hepatocellular carcinoma

in review 4 min read Updated 2026-10-28
hepatocellular carcinoma

Survey only people who would be treated: cirrhosis of any cause (Child-Pugh A–B, or C if transplant candidate) and chronic HBV in the CASL 2025 groups. US + AFP every 6 months. Lesion ≥1 cm or AFP ≥20 / rising → multiphase CT or MRI. In cirrhosis or HBV, LI-RADS 5 = HCC without biopsy. Staging and treatment follow BCLC: resection, ablation or transplant (early) → TACE (intermediate) → atezolizumab–bevacizumab or durvalumab–tremelimumab (advanced) → best supportive care.

who to survey

Surveillance only helps if the patient would be a candidate for treatment.

groupsurvey?
cirrhosis, any aetiology, Child-Pugh A–Byes
Child-Pugh Conly if transplant candidate; all listed patients
HCV cirrhosis after SVRyes — lifelong
HBV without cirrhosis (CASL 2025)men ≥40 · women ≥50 · African ancestry ≥30 · first-degree relative with HCC (from 40, or 10 years before relative’s age at diagnosis) · HIV coinfection ≥40 · HDV coinfection ≥40 (earlier if F3+)
HCV post-SVR with F3, no cirrhosisno (not routine)
MASLD with advanced fibrosis, no cirrhosisno (not routine)
haemochromatosis without cirrhosisno
life-limiting comorbidity not fixable by transplantno

HBV surveillance continues on antivirals and even after HBsAg loss if cirrhotic.

how

  • Ultrasound + AFP every 6 months. CT/MRI and other biomarkers are not routine.
  • Report US visualisation quality; poor visualisation (obesity, MASLD, nodular liver) → contrast MRI or multiphase CT instead.
  • Underuse is the main failure — recall systems and outreach improve adherence.

recall

findingnext step
lesion <1 cmrepeat US + AFP in 3–6 months; stable ×2 → back to 6-monthly
lesion ≥1 cmmultiphase CT or contrast MRI
AFP ≥20 µg/L or risingmultiphase CT or contrast MRI

diagnosis

In cirrhosis or chronic HBV, HCC is diagnosed on imaging alone — arterial-phase hyperenhancement with washout and/or capsule (LI-RADS). Outside these groups, imaging isn’t accurate enough → biopsy.

LI-RADSmanagement
LR-1 / LR-2benign / probably benign → routine surveillance
LR-3repeat CT/MRI in 3–6 months
LR-4multidisciplinary review; repeat imaging ≤3 months or biopsy
LR-5HCC — treat without biopsy
LR-Mmalignant, not HCC-specific → biopsy (cholangiocarcinoma, mixed tumour)

AFP alone doesn’t diagnose HCC.

staging and treatment

Stage with multiphase CT/MRI of the abdomen + CT chest (beyond stage 0). No routine PET or bone scan. BCLC integrates tumour burden, liver function (Child-Pugh, portal hypertension) and ECOG.

flowchart TD
  A[HCC] --> B{BCLC stage}
  B -->|0–A: single or ≤3 nodules ≤3 cm, ECOG 0, preserved liver function| C{portal hypertension or decompensation?}
  C -->|no| D[resection]
  C -->|yes, within Milan| E[liver transplant]
  C -->|not a surgical candidate| F[thermal ablation ≤3 cm · radioembolisation]
  B -->|B: multinodular, ECOG 0| G[TACE]
  B -->|C: vascular invasion or spread, ECOG 1–2| H[systemic therapy]
  B -->|D: Child-Pugh C not transplantable, ECOG 3–4| I[best supportive care]
  G -->|progression or unsuitable| H
  • Resection: no cirrhosis, or well-compensated cirrhosis without CSPH.
  • Transplant: early HCC with CSPH or decompensation (Milan: single ≤5 cm, or ≤3 nodules each ≤3 cm, no vascular invasion). Treats both the cancer and the cirrhosis. Bridging locoregional therapy while listed.
  • Ablation (radiofrequency or microwave) = treatment of choice for ≤3 cm when surgery isn’t possible.
  • TACE for BCLC B; radioembolisation an alternative.
  • Systemic, Child-Pugh A, ECOG 0–1: atezolizumab + bevacizumab or durvalumab + tremelimumab first-line. Bevacizumab → EGD first; treat high-risk varices (≥1 banding session) or choose durvalumab–tremelimumab if recent GI bleed. Tyrosine kinase inhibitors (lenvatinib, sorafenib) when immunotherapy is contraindicated. Well-selected Child-Pugh B only.
  • No adjuvant or neoadjuvant systemic therapy with resection or ablation — the IMbrave050 recurrence-free survival benefit didn’t hold up (AASLD 2025 update). Surveillance for recurrence is the standard after curative treatment.
  • Child-Pugh C not transplantable → palliative care; advance care planning for all.

prevention

  • HBV vaccination; treat HBV and cure HCV (lowers but doesn’t abolish risk).
  • Weight, diabetes and alcohol control; stop smoking.
  • Coffee associated with lower HCC risk — reasonable to encourage.
  • Statins, aspirin and metformin: not for HCC prevention alone; don’t stop them in cirrhosis if otherwise indicated.

Prepared 2026-10-28. Not yet verified — check every number against the sources.

Key references

Suggest a correction hepatocellular carcinoma